A Doxorubicin-Glucuronide Prodrug Released from Nanogels Activated by High-Intensity Focused Ultrasound Liberated β-Glucuronidase

The poor pharmacokinetics and selectivity of low-molecular-weight anticancer drugs contribute to the relatively low effectiveness of chemotherapy treatments. To improve the pharmacokinetics and selectivity of these treatments, the combination of a doxorubicin-glucuronide prodrug (DOX-propGA3) nanoge...

Descripción completa

Detalles Bibliográficos
Autores principales: Besse, Helena C., Chen, Yinan, Scheeren, Hans W., Metselaar, Josbert M., Lammers, Twan, Moonen, Chrit T. W., Hennink, Wim E., Deckers, Roel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355552/
https://www.ncbi.nlm.nih.gov/pubmed/32532061
http://dx.doi.org/10.3390/pharmaceutics12060536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355552/
https://www.ncbi.nlm.nih.gov/pubmed/32532061
http://dx.doi.org/10.3390/pharmaceutics12060536

Ejemplares similares